Targeting a protein to improve treatment for pancreatic cancer
A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy
This study is looking at how a certain protein in pancreatic cancer cells affects their ability to get nutrients, with the hope that by blocking this protein, we can find new ways to help treat pancreatic cancer by starving the cancer cells.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11045056 on NIH RePORTER |
What this research studies
This research focuses on pancreatic cancer, which is currently incurable. It aims to understand how a specific transmembrane protein affects the nutrient supply to cancer cells, potentially leading to new treatment strategies. By blocking this protein, the researchers hope to starve the cancer cells and induce cell death. The study will involve developing new therapeutic agents that target this protein, using various preclinical models to evaluate their effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer who may benefit from novel therapeutic approaches.
Not a fit: Patients with other types of cancer or those who are not diagnosed with pancreatic cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving survival rates and patient outcomes.
How similar studies have performed: While targeting transmembrane proteins is a promising approach, this specific strategy in pancreatic cancer is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Yao, Wantong — University of Tx Md Anderson Can Ctr
- Study coordinator: Yao, Wantong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.